ZURICH, May 25 (Reuters) - Roche Holding AG's potential blockbuster drug Mircera has been cleared by European authorities, who recommended allowing sales to treat anaemia linked to kidney disease.
-- Dose Adjustments Considered to be one of the Main Causes of Haemoglobin Instability in Chronic Kidney Disease Patients A new analysis has shown that once-monthly Mircera(R) maintains stable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results